CD52 expression by IHC / flow
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CD52-IHC |
|---|---|
| Type | Biomarker |
| Aliases | CD52 expressionЕкспресія CD52 (ІГХ / проточна цитометрія) |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodFlow cytometry on PB/BM OR IHC on FFPE Unitscategorical (positive | negative); semi-quantitative % |
| Related biomarkers | None declared |
Notes
Cross-disease relevance — alemtuzumab target: - **CLL**: alemtuzumab (anti-CD52) historically used for fludarabine- refractory CLL; almost obsolete now in BTKi/VenO era but option for select r/r cases. - **T-cell prolymphocytic leukemia (T-PLL)**: alemtuzumab is standard-of-care 1L (~80% response rate) — a rare T-cell entity. - **Sézary syndrome**: alemtuzumab option for refractory. - **B-cell lymphomas variably express**. Profound + prolonged immunosuppression on alemtuzumab — mandatory PJP + HSV/VZV + CMV-DNA monitoring. Future scope: T-PLL workstream when rare-disease module lands.
Used By
Indications
IND-T-PLL-1L-ALEMTUZUMAB- IND-T-PLL-1L-ALEMTUZUMABIND-T-PLL-2L-VENETOCLAX-ALEMTUZUMAB- IND-T-PLL-2L-VENETOCLAX-ALEMTUZUMAB
Questionnaires
QUEST-T-PLL-1L-STUB- T-Cell Prolymphocytic Leukemia — first line